Concorde Asset Management LLC Invests $1.02 Million in Health Catalyst, Inc. (NASDAQ:HCAT)

Concorde Asset Management LLC bought a new stake in Health Catalyst, Inc. (NASDAQ:HCAT) in the 3rd quarter, Holdings Channel reports. The institutional investor bought 27,970 shares of the company’s stock, valued at approximately $1,024,000.

Several other institutional investors also recently made changes to their positions in HCAT. Winslow Evans & Crocker Inc. acquired a new position in shares of Health Catalyst in the 2nd quarter worth approximately $32,000. Nisa Investment Advisors LLC bought a new stake in shares of Health Catalyst in the 3rd quarter worth $51,000. Advisor Group Holdings Inc. grew its stake in shares of Health Catalyst by 415.8% in the 2nd quarter. Advisor Group Holdings Inc. now owns 2,388 shares of the company’s stock worth $70,000 after acquiring an additional 1,925 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Health Catalyst by 80.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,555 shares of the company’s stock worth $75,000 after acquiring an additional 1,140 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its stake in shares of Health Catalyst by 73.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,850 shares of the company’s stock worth $83,000 after acquiring an additional 1,210 shares in the last quarter. 85.53% of the stock is currently owned by institutional investors.

In other Health Catalyst news, CEO Daniel D. Burton sold 84,742 shares of the stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $34.85, for a total transaction of $2,953,258.70. Following the transaction, the chief executive officer now directly owns 199,662 shares in the company, valued at $6,958,220.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Linda Llewelyn sold 2,242 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $35.46, for a total transaction of $79,501.32. Following the transaction, the insider now owns 27,619 shares in the company, valued at $979,369.74. The disclosure for this sale can be found here. Insiders sold 764,968 shares of company stock worth $24,863,791 over the last ninety days. 22.10% of the stock is currently owned by insiders.

HCAT traded down $0.70 on Monday, reaching $33.82. The company had a trading volume of 1,268 shares, compared to its average volume of 654,231. The business has a 50 day simple moving average of $35.02 and a 200 day simple moving average of $31.36. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -11.54 and a beta of 0.54. The company has a debt-to-equity ratio of 0.70, a quick ratio of 7.91 and a current ratio of 7.91. Health Catalyst, Inc. has a 52-week low of $17.48 and a 52-week high of $41.26.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.24. The business had revenue of $43.26 million for the quarter, compared to the consensus estimate of $42.19 million. Health Catalyst had a negative net margin of 46.91% and a negative return on equity of 20.74%. Health Catalyst’s quarterly revenue was up 17.5% on a year-over-year basis. During the same period last year, the firm posted ($0.21) earnings per share. As a group, equities research analysts predict that Health Catalyst, Inc. will post -1.68 EPS for the current fiscal year.

HCAT has been the subject of several research reports. Citigroup initiated coverage on shares of Health Catalyst in a research report on Tuesday, July 14th. They set a “buy” rating and a $40.00 price target for the company. Truist Financial increased their target price on shares of Health Catalyst from $36.00 to $43.00 in a research report on Wednesday, August 12th. BidaskClub lowered shares of Health Catalyst from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 7th. Guggenheim increased their price target on shares of Health Catalyst from $33.00 to $37.00 in a report on Tuesday, August 18th. Finally, Stifel Nicolaus increased their price target on shares of Health Catalyst from $36.00 to $37.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $38.82.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was founded in 2008 and is headquartered in Salt Lake City, Utah.

See Also: What does a dividend yield signify to investors?

Want to see what other hedge funds are holding HCAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Health Catalyst, Inc. (NASDAQ:HCAT).

Institutional Ownership by Quarter for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.